Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 323 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dex Clear all
Active, not recruiting Phase 3 Interventional Results available

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

NCT02339740
View directory record Official record
Conditions
Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Interventions
Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tretinoin
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
152
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 2, 2026, 10:06 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of DEX-IN During Outpatient Procedures

NCT03348423
View directory record Official record
Conditions
Pain
Interventions
DEX-IN, Fentanyl, Placebo
Drug
Lead sponsor
Baudax Bio
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Sep 2, 2026, 10:06 AM EDT
Active, not recruiting Phase 1 Interventional

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

NCT03740334
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia ALL
Interventions
Ribociclib, Dexamethasone, Everolimus
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year to 30 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Aurora, Colorado • Wilmington, Delaware • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 2, 2026, 10:06 AM EDT
Completed Phase 1 Interventional

Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01689987
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Cyclophosphamide, Dexamethasone, Hydroxychloroquine, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Sep 2, 2026, 10:06 AM EDT
Terminated Phase 2 Interventional Results available

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

NCT04407442
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Azacitidine, Daratumumab, Dexamethasone
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 2, 2026, 10:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

NCT00477412
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Bortezomib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Methotrexate, Rituximab, Vincristine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 79 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 2, 2026, 10:06 AM EDT
Completed Phase 2 Interventional Results available

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01816971
View directory record Official record
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
dexamethasone, carfilzomib, lenalidomide, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 2, 2026, 10:06 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study of Dexmedetomidine After Intra-Nasal and Buccal Dosing in Children

NCT03668951
View directory record Official record
Conditions
Heart Diseases
Interventions
Dexmedetomidine buccal, Dexmedetomidine Intranasal
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Months to 48 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 2, 2026, 10:06 AM EDT
Completed Phase 3 Interventional Results available

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

NCT01078454
View directory record Official record
Conditions
Light Chain Deposition Disease, Primary Systemic Amyloidosis
Interventions
melphalan, dexamethasone, bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
209
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Aurora, Colorado + 140 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 2, 2026, 10:06 AM EDT
Completed Phase 2 Interventional

Investigation of Sleep in the Intensive Care Unit

NCT03355053
View directory record Official record
Conditions
Delirium, Sleep
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 2, 2026, 10:06 AM EDT
Terminated Phase 2 Interventional Results available

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

NCT03457142
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Abatacept, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Buffalo, New York • East Hills, New York • West Islip, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 2, 2026, 10:06 AM EDT
Active, not recruiting Phase 2 Interventional

Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors

NCT05139043
View directory record Official record
Conditions
Malignant Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain, Recurrent Malignant Brain Neoplasm
Interventions
Dexamethasone
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 2, 2026, 10:06 AM EDT
Terminated Not applicable Interventional

Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy

NCT02550119
View directory record Official record
Conditions
Malignant Digestive System Neoplasm, Nausea and Vomiting
Interventions
Aprepitant, Dexamethasone, Dolasetron Mesylate, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 2, 2026, 10:06 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Dexamethasone in Controlling Dyspnea in Patients With Cancer

NCT03367156
View directory record Official record
Conditions
Dyspnea, Malignant Neoplasm
Interventions
Dexamethasone, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 2, 2026, 10:06 AM EDT
Completed No phase listed Observational

Lymphedema Specific PROs for Risk Assessment, Prevention and Early Detection

NCT05929001
View directory record Official record
Conditions
Lymphedema
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 2, 2026, 10:06 AM EDT
Completed Phase 2 Interventional

Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer

NCT00003753
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
dexamethasone, floxuridine, irinotecan hydrochloride, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 2, 2026, 10:06 AM EDT
Completed Phase 1 Interventional

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

NCT01711528
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma
Interventions
Bortezomib, Dexamethasone, Dinaciclib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Scottsdale, Arizona • Rochester, Minnesota • Houston, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 2, 2026, 10:06 AM EDT
Completed Early Phase 1 Interventional

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

NCT02921893
View directory record Official record
Conditions
Plasmacytoma, POEMS Syndrome
Interventions
Dexamethasone, Ixazomib Citrate, Lenalidomide, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 2, 2026, 10:06 AM EDT
Completed Phase 1 Interventional

Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer

NCT00059930
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
FOLFOX regimen, dexamethasone, floxuridine, fluorouracil, leucovorin calcium, oxaliplatin, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2025
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 2, 2026, 10:06 AM EDT
Not listed Not applicable Interventional

The Use of Bioimpedance to Determine Pre-Clinical Lymphedema in the Post-Operative Breast Cancer Patient

NCT01521000
View directory record Official record
Conditions
Breast Cancer
Interventions
Garment Sleeve
Device
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2012 · Synced Sep 2, 2026, 10:06 AM EDT
Completed Not applicable Interventional Results available

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

NCT00343863
View directory record Official record
Conditions
Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
palonosetron hydrochloride, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications, ondansetron hydrochloride, survey administration
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 2, 2026, 10:06 AM EDT
Completed Phase 1 Interventional

Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma

NCT02697344
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study, R-(-)-Gossypol Acetic Acid
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Sep 2, 2026, 10:06 AM EDT
Completed Phase 1 Interventional

Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

NCT00693433
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
dexamethasone, temsirolimus, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Las Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Sep 2, 2026, 10:06 AM EDT
Withdrawn Phase 1 Interventional

Dexamethasone as an Immediate Intervention

NCT02753166
View directory record Official record
Conditions
Trauma
Interventions
Dexamethasone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Sep 2, 2026, 10:06 AM EDT